This disclosure relates to methods of treating and diagnosing esophageal cancer based on expression levels of biomarker miRNAs. An aspect of the present disclosure is directed to a method of treating esophageal cancer (EC) in a patient, the method comprising: comparing the level of one or more miRNAs in a sample of a patient with a level of miR-15b miR-17, mir-18a, mir-21, mir-23a, mir-24-2, mir-25, mir-27a, mir-93, mir- Mir-181b, mir-182, mir-183, mir-192, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir- mir-194-1, mir-194-2, mir-196a-1, mir-196a-2, mir-196b, mir-205, mir-215, mir- One or more miRNA expression levels selected from the group consisting of -338, mir-375, mir-421, mir-484, mir-505, mir-769, mir-944, mir-1468, mir- Diagnosing the patient as an esophageal cancer patient； And administering an effective amount of the therapeutic agent for esophageal cancer in the diagnosed patient.본 개시는 바이오 마커 miRNA의 발현 수준에 기초한 식도암 치료 및 진단 방법에 관한 것이다. 본 개시의 양태는 환자에서 식도암 (EC)을 치료하는 방법에 관한 것으로서, 상기 방법은 다음을 포함한다: 환자가, 대조군 샘플에서의 하나 이상의 miRNA 발현 수준에 비교하여, 환자의 샘플에서 mir-15b, miR-17, mir-18a, mir-21, mir-23a, mir-24-2, mir-25, mir-27a, mir-93, mir-103, mir-106b, mir-129-2, mir-139, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir-181a, mir-181b-1, mir-181b, mir-182, mir-183, mir-192, mir-194-1, mir-194-2, mir-196a-1, mir-196a-2, mir-196b, mir-205, mir-215, mir-223, mir-224, mir-335, mir-338, mir-375, mir-421, mir-484, mir-505, mir-769, mir-944, mir-1468, mir-3648, 및 let-7i로부터 선택된 하나 이상의 miRNA 발현 수준이 상승하거나 감소된 것으로 판정되었을 때 식도암 환자로 진단하는 단계； 및 상기 진단된 환자에서 유효량의 식도암 치료제를 투여하는 단계.
